Quillivant XR was approved by the FDA in 2012 for the treatment of attention deficit disorder (ADHD or ADD) in children, adolescents, and adults. Originally developed and manufactured by NextWave Pharmaceuticals — and later acquired by Pfizer — Quillivant XR is the first once-daily extended-release formulation of liquid methylphenidate, made primarily for the one-third of children under 12 who cannot swallow pills or capsules. It is useful for people who need finely tuned dosing that only a liquid formulation can provide.
Quillivant XR delivers exactly the same medication, over much the same length of time, as other methylphenidate extended-release formulations that come in pills and capsules, such as Concerta, Ritalin LA, and so on. Quillivant XR was made available in pharmacies in January 2013. NextWave is also developing a chewable tablet formulation of methylphenidate.
If you or your child has problems taking pills and need longer-term coverage, Quillivant XR may be right for you. Talk with your doctor.
For more information about Quillivant XR, see the FDA’s Quillivant XR Medication Guide.
Leave your review of Quillivant XR in the ADHD Medication User Reviews.